Why does surfactant increase tidal volume

Pediatrics ; 2 : - Closure of the ductus arteriosus and mechanics of breathing in preterm infants after surfactant replacement therapy. Pediatr Res ; 25 3 : - Multicenter trial of single-dose modified bovine surfactant extract Survanta for prevention of respiratory distress syndrome.

Pediatrics ; 85 6 : - Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation. Raju TN , Langenberg P. Pulmonary hemorrhage and exogenous surfactant therapy: a meta analysis.

J Pediatr ; 4 : - Association between neonatal care practices and efficacy of exogenous human surfactant: results of a bicenter randomized trial. Pediatrics ; 91 3 : - Energy expenditure during synthetic surfactant replacement therapy for neonatal respiratory distress syndrome. J Pediatr ; 2 Pt 2 : S29 - S A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome.

J Pediatr ; 5 : - Surfactant therapy in full-term neonates with severe respiratory failure. Pediatrics ; 92 1 : - Controlled trial of a single dose of synthetic surfactant at birth in premature infants weighing to grams.

J Pediatr ; 2 Pt 2 : S3 - S Single- versus multiple-dose surfactant replacement therapy in neonates of 30 to 36 weeks' gestation with respiratory distress syndrome.

Pediatrics ; 86 4 : - Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in to gram infants with respiratory distress syndrome.

Pulmonary mechanics in premature infants one month after treatment with synthetic surfactant. J Pediatr ; 2 Pt 2 : S25 - Clinical diagnosis and management of respiratory distress in preterm neonates: effect of participation in a controlled trial. Pediatrics ; 90 3 : - Cerebroelectrical depression following surfactant treatment in preterm neonates. Pediatrics ; 89 4 Pt 1 : - Early versus late surfactant replacement therapy in severe respiratory distress syndrome.

Lung ; Suppl : - Comparison of three dosing procedures for administration of bovine surfactant to neonates with respiratory distress syndrome. J Pediatr ; 3 : - Beneficial effect of exogenous surfactant in infants suffering acute respiratory distress syndrome after cardiac surgery. Eur J Cardiothorac Surg ; 40 3 : - Multicenter, randomized, controlled study of porcine surfactant in severe respiratory syncytial virus-induced respiratory failure.

Pediatr Crit Care Med ; 3 3 : - Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf. Pediatrics ; 89 1 : 13 - Surfactant replacement therapy on ECMO does not improve outcome in neonates with congenital diaphragmatic hernia.

J Pediatr Surg ; 39 11 : - Surfactant does not improve survival rate in preterm infants with congenital diaphragmatic hernia. J Pediatr Surg ; 39 6 : - Van Meurs K.

Is surfactant therapy beneficial in the treatment of the term newborn infant with congenital diaphragmatic hernia?

Surfactant therapy and intracranial hemorrhage: review of the literature and results of new analyses. Pulmonary hemorrhage in premature infants after treatment with synthetic surfactant: an autopsy evaluation.

J Pediatr ; 2 Pt 2 : S40 - Treatment investigational new drug experience with Survanta beractant. Surfactant and patent ductus arteriosus. Indian J Pediatr ; 77 1 : 51 - Immediate improvement in lung volume after exogenous surfactant: alveolar recruitment versus increased distention.

Surfactant use for premature infants with respiratory distress syndrome in three New York city hospitals: discordance of practice from a community clinician consensus standard. J Perinatol ; 30 9 : - Pulmonary mechanics and energetics in preterm infants who had respiratory distress syndrome treated with synthetic surfactant.

J Pediatr ; 2 Pt 2 : S18 - S Effect of single dose surfactant on pulmonary function. Crit Care Med ; 18 6 : - Long-term pulmonary consequences of respiratory distress syndrome in preterm infants treated with exogenous surfactant.

Delayed compliance increase in infants with respiratory distress syndrome following synthetic surfactant. Pediatr Pulmonol ; 14 4 : - Compliance of the respiratory system in newborn infants pre- and postsurfactant replacement therapy. Pediatr Pulmonol ; 15 4 : - Lung mechanics and gas exchange in ventilated preterm infants during treatment of hyaline membrane disease with multiple doses of artificial surfactant Exosurf.

Pediatr Pulmonol ; 14 1 : 10 - Respiratory function at follow-up after neonatal surfactant replacement therapy. Respir Med ; 87 3 : - Pulmonary hemodynamics after synthetic surfactant replacement in neonatal respiratory distress syndrome. Positive end-expiratory pressure and surfactant decrease lung injury during initiation of ventilation in fetal sheep.

Pump administration of exogenous surfactant: effects on oxygenation, heart rate, and chest wall movement of premature infants. J Perinatol ; 13 3 : - Soll R , Ozek E. Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome.

Surfactant for respiratory distress syndrome: are there important clinical differences among preparations? Curr Opin Pediatr ; 19 2 : - Overview of surfactant replacement trials. J Perinatol ; 25 Suppl 2 : S40 - S These structures are also important for some processing of surfactant proteins, which is necessary for the proteins to mature and become functional.

Surfactant is released from the lung cells and spreads across the tissue that surrounds alveoli. This substance lowers surface tension, which keeps the alveoli from collapsing after exhalation and makes breathing easy.

These two proteins help spread the surfactant across the surface of the lung tissue, aiding in the surface tension-lowering property of surfactant. In addition, SP-B plays a role in the formation of lamellar bodies. These mutations lead to a reduction in or absence of mature SP-B. These changes lead to abnormal surfactant composition and decreased surfactant function.

The loss of functional surfactant raises surface tension in the alveoli, causing severe breathing problems. It is unclear which of these outcomes causes the signs and symptoms of SP-C dysfunction. Lack of mature SP-C can lead to abnormal composition of surfactant and decreased surfactant function.

Alternatively, research suggests that abnormally processed SP-C proteins form the wrong three-dimensional shape and accumulate inside the lung cells. These misfolded proteins may trigger a cellular response that results in cell damage and death. This damage may disrupt surfactant production and release. The ABCA3 gene provides instructions for making a protein that is found in the membrane that surrounds lamellar bodies. The ABCA3 protein transports phospholipids into lamellar bodies where they form surfactant.

The ABCA3 protein also appears to be involved in the formation of lamellar bodies. ABCA3 gene mutations, which cause a type of surfactant dysfunction sometimes referred to as ABCA3 deficiency, lead to reduction or absence of the protein's function. Without ABCA3 protein function, the transport of surfactant phospholipids is decreased.

ABCA3 gene mutations result in abnormal surfactant composition and function. It has been suggested that mutations that eliminate ABCA3 protein function cause severe forms of surfactant dysfunction, and mutations that leave some residual ABCA3 activity cause milder forms of the condition.

When caused by mutations in the SFTPB or ABCA3 gene, this condition is inherited in an autosomal recessive pattern , which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

When caused by mutations in the SFTPC gene, this condition has an autosomal dominant inheritance pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. Surfactant Administration in the NICU Introduction Aim Definition of Terms Assessment Dosing Management Special Considerations Companion Documents Links Evidence Table References Introduction Pulmonary surfactant is a complex mixture of phospholipids and proteins that creates a cohesive surface layer over the alveoli which reduces surface tension and maintains alveolar stability therefore preventing atelectasis.

Aim The aim of this guideline is to outline the principles of surfactant replacement therapy and the safe administration of surfactant in neonates in the Butterfly ward - Newborn Intensive Care Unit NICU Definition of Terms Neonate — infant less than 28 days old Surfactant - complex and highly surface active material composed of lipids and proteins which is found in the fluid lining the alveolar surface of the lungs, which serves to reduce alveolar surface tension RDS — respiratory distress syndrome FiO 2 - fraction of inspired oxygen Assessment Clinical indications Surfactant replacement therapy should be considered in: neonates with clinical and radiographic evidence of RDS neonates at risk of developing RDS e.

Auscultation of the chest for equal bilateral air entry confirmed by a NICU fellow or consultant is an additional method of confirming ETT placement If neonate is not intubated e. Refer to the guideline on elective intubation. Check and prepare emergency equipment at bedside e. Neopuff, suction. Ensure patency of ETT. Suction ETT as necessary prior to administration.

Slowly warm the vial of surfactant to room temperature before administration, visually inspect suspension for discolouration, should be creamy to white. Remove plastic cap, clean the rubber vial top with an alcohol swab. Inform parent s Administration On clean surface gather and prepare equipment for procedure Perform hand hygiene Open aseptic field and peel open sterile equipment and drop onto aseptic field Perform hand hygiene and administering medical practitioner or NNP dons sterile gloves.

Using surgical aseptic technique, cut the 4Fr tube from the surfactant kit or a 5Fr feeding tube to length using the tape measure so that the tip lies 1 cm above the end of the endotracheal tube. This ensures that the surfactant is administered intra-tracheal. Curosurf should not be instilled into a main stem bronchus. With vial held by assistant operator slowly draw up a little over the required dose of surfactant into the 3mL or 5mL syringe using the needle free device or a large-gauge needle.

Attach the pre-cut tube to this syringe, prime or fill the tube with surfactant to the end. Discard excess surfactant through the attached tube so that only the dose to be given remains in the syringe. Ensure bed is flat. Place the neonate in supine position.

There is no evidence to support the practice of placing the neonate in multiple positions during administration.